5HT3 Antagonism and Auditory Gating in Schizophrenia
Information source: Department of Veterans Affairs
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: ondansetron (Drug); neuropsychological testing (Behavioral); nicotine (Drug); haloperidol (Drug)
Sponsored by: Department of Veterans Affairs
The target groups in this study are brain waves and neurotransmitters (chemical messengers)
in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will
help understand more about normal brain functioning and how that functioning differs in
people with schizophrenia. Another purpose of this study is to determine how the altered
brain functioning in schizophrenia contributes the symptoms found in the illness.
Official title: 5HT3 Antagonism and Auditory Gating in Schizophrenia
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Minimum age: 18 Years.
Maximum age: 55 Years.
Subjects with diagnosed with schizophrenia will be studied.
Locations and Contacts
VAMC, Denver, Colorado 80013, United States
Starting date: June 1998
Last updated: January 20, 2009